Nuclear Medicine Focus Cyclopharm is a ASX-listed medical device company specializing in nuclear medicine with Technegas as its flagship lung ventilation imaging product, presenting a clear entry point for partnerships with radiology and nuclear medicine departments seeking advanced ventilation imaging solutions.

Growth Opportunities The pipeline expansion with Ultralute aims to improve radiopharmaceutical production efficiency, offering a potential upsell to PET/SPECT facilities and contract manufacturers looking to optimize throughput and cost per dose.

Clinical Expansion Technegas is being used primarily for pulmonary embolism diagnosis but is being investigated for COPD, asthma, CTEPH, and post-lung intervention assessment, signaling opportunities to target clinics and hospitals expanding indications and requiring robust imaging agents.

SME Market Position With a lean headcount (11-50) and revenue under one million, Cyclopharm presents a compelling target for distributors and regional sales partnerships to accelerate penetration in smaller to mid-size hospitals and imaging centers.

Competitive Landscape Comparable peers include Clarity Pharmaceuticals and larger global players; this creates an opportunity to position Technegas as a specialized, high-value imaging agent in competitive bids and value-based purchasing agreements.